Study design

prospective comparative non-randomized trial

Study time

2018.1-2020.1

Country

Italy

Object

histological diagnosis of prostatic adenocarcinoma, no distant metastases at clinical staging, RP as chosen primary treatment option, estimated life-expectancy of ≥10 years.

Inclusion criteria

androgen deprivation therapies, chemotherapies, pelvic radiation therapies or treatments that could influence prostate tumor growth

Sample size

134

Topic classification

Comparison of surgical techniques

Keypoint

Comparing LRP-NS with RARP-NS in a high-volume single center, the expectation/satisfaction ratio is in favor of LRP. Worse oncologic preoperative characteristics in the RARP group may influence the higher incidence of SM+.

Year